Periprosthetic Joint Infection Clinical Trial
Official title:
Preoperative Daptomycin Prophylaxis for Preventing Gram-Positive or Methicillin-Resistant Staphylococcus Aureus Infection in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
The gold standard for treating prosthetic joint infection (PJI) is two-stage exchange arthroplasty. This includes the first stage of debridement and removal of the artificial joint, and the second stage of reimplantation of the artificial joint. Methicillin-resistant staphylococcus aureus (MRSA) infection is one of the factors leading to the failure of artificial joint infection treatment. Before the second stage of the joint surgery, the surgeon will prescribe prophylactic antibiotics based on previous bacterial cultures. The usual preoperative antibiotic is a first-generation cephalosporin antibiotic. If it is MRSA, vancomycin will be given. Increasingly, literature reports link prosthetic joint infections to MRSA, but no changes have been made to the routine recommendation for MRSA prophylactic antibiotic use. Daptomycin is a cyclic lipopeptide antibiotic that can rapidly penetrate biofilms and bones, and its safety and tolerability have been confirmed. Therefore, it can effectively combat Gram-positive organisms, including MRSA. Daptomycin has many characteristics of an ideal prophylactic: short infusion time, low adverse events during administration, and a range limited to Gram-positive organisms. We aim to assess whether adding antibiotics that cover MRSA would reduce prosthetic joint infections and increase surgical success rates, in addition to the standard recommended prophylactic antibiotics. Thus, this prospective randomized trial is designed to assess, besides using the first-generation cephalosporin antibiotic, the effects of adding an antibiotic with MRSA coverage (Daptomycin vs. Vancomycin).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06126614 -
Infection Prophylaxis in Total Joint Replacement
|
Phase 3 | |
| Recruiting |
NCT02530229 -
Arthrocentesis Study
|
N/A | |
| Enrolling by invitation |
NCT05640336 -
Treatment of Acute Periprosthetic Joint Infection Comparing Single and Planned Double-Debridement Antibiotics and Implant Retention Followed by Chronic Antibiotic Suppression
|
N/A | |
| Completed |
NCT03139539 -
Intraoperative Microbial Contamination
|
N/A | |
| Recruiting |
NCT06268795 -
A Diagnostic Test Accuracy Study Comparing Biopsy to Aspiration in Shoulder and Elbow Arthroplasty Revision Surgery (BASE Study)
|
||
| Recruiting |
NCT05357287 -
Closed Incisional Negative Pressure Wound Therapy in Post-surgical Wound Care of Patients With Periprosthetic Joint Infection
|
N/A | |
| Active, not recruiting |
NCT05084378 -
Evaluation of Emerging New Treatments for Infection Prevention in Total Joint Replacement
|
Phase 3 | |
| Recruiting |
NCT02868736 -
Clinical Validation of CD Diagnostics Synovasure PJI ELISA Test and Synovasure PJI Lateral Flow Test for Detection of Periprosthetic Joint Infection in Synovial Fluid
|
N/A | |
| Terminated |
NCT04274517 -
Microbial Growth in Operative Splash Basins During Total Joint Arthroplasty
|
N/A | |
| Recruiting |
NCT05284318 -
Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.
|
||
| Enrolling by invitation |
NCT05320354 -
Diagnosis and Bacterial Identification of Periprosthetic Joint Infection With Microbial-ID
|
||
| Recruiting |
NCT05495815 -
Proper Duration of Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention
|
N/A |